Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00055055|
Recruitment Status : Completed
First Posted : February 17, 2003
Last Update Posted : May 26, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This study will examine families in which one sibling of a sibling pair, or twin pair, has developed a systemic rheumatic disease and one has not, to see if and how the two differ in the following:
- Blood cell metabolism;
- Types of cells in the blood;
- Environmental exposures or genetic factors that might explain why one developed disease and the other did not.
Families in which one sibling has developed a systemic rheumatic disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, dermatomyositis, or myositis, and the other has not, are eligible for this study. The siblings may or may not be twins, but must be of the same gender and be within a 5-year age difference. Biological parents, or, in some cases, children, will also be included in the study. Normal, healthy volunteers will serve as control subjects.
Participants will undergo some or all of the following tests and procedures:
- Medical history and physical examination. Participants will also be asked permission to obtain medical records for review.
- Questionnaires about environmental exposures at work, at home, and elsewhere. Probands (participants with rheumatic disease) and their healthy siblings will also answer questions about infections, vaccinations, medications or dietary supplements, sun exposure, and stressful events during the year before disease diagnosis in the affected sibling.
- Blood and urine collection for the following tests:
- Routine blood chemistries and other studies to rule out certain diseases or medical problems;
- Evidence of past toxic exposures and certain infections;
- Presence of cells from the mother in the child s blood and vice versa. (Recent studies suggest that during pregnancy or delivery, cells from the mother and baby may be exchanged and circulate in the body for many years, possibly causing problems);
- In twin or sibling pairs, presence of certain genes that may be more common in patients with systematic rheumatic diseases as compared with their unaffected siblings and normal volunteers;
- In identical twins, comparison of their blood cell metabolism to see if and how the metabolism differs in people with rheumatic disease.
Participants may be asked for permission to have some of their blood and urine samples stored and to obtain previously collected blood or tissue biopsy specimens that are no longer needed for clinical care, for research purposes. They may also be asked to give additional blood or urine samples.
Participants will be followed every year for 5 years (either in person or by questionnaire) to evaluate any changes in their condition. The final 5-year evaluation will repeat some of the questionnaires and procedures described above.
|Condition or disease|
|Rheumatoid Arthritis Systemic Lupus Erythematosus Idiopathic Inflammatory Myopathies|
|Study Type :||Observational|
|Actual Enrollment :||1056 participants|
|Official Title:||Pathogenic Studies In Families With Twins Or Siblings Discordant For Systemic Rheumatic Disorders|
|Actual Study Start Date :||April 21, 2003|
A healthy individual who has not used any NSAIDS, with no infectious disease, or severe trauma within 8 weeks of enrollment, doesn't have a first degree relatives with RA, SLE, SSc or IIM
Parent of Proband
Biological mother or father of the proband who is willing to enroll in the study
Primary Unaffected Dizygous Twin
Dizygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
Primary Unaffected Monozygous Twin
Monozygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
Primary Unaffected Non-twin Sibling
Sibling of the same biological parents, same gender, within 5 years of age of the proband who does not meet criteria for one of the rheumatic diseases
Proband should have documented evidence that he/she meets criteria for adult and juvenile forms of systemic rheumatic disorders
- Physician Global Assesment Questionnaire [ Time Frame: At enrollment and each study ]Evaluate core set disease activity, damage and quality of life measures in adult and juvenile myositis patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||2 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- INCLUSION CRITERIA:
The minimum inclusion criteria needed for enrollment are a twin pair or sibling pair, as defined by an eligible proband and his/her eligible twin or sibling, willing and able to give informed consent, to enroll in the study, to complete the questionnaires and to donate blood and urine samples (in case of children, parent/legal guardian must also be willing and able to provide informed consent).
Proband inclusion criteria:
- Children (< 18 years of age) or adults (18 or more years of age) require a diagnosis of a systemic rheumatic disorder (by American College of Rheumatology (ACR) or other criteria for the adult or juvenile forms of RA, SLE, SSc, or IIM (per (92;93)). Regarding the childhood-onset diseases: JRA will be defined by age of onset <17 years of age; for other diseases age of onset will be < 18 years. Probands will be diagnosed within 5 years of enrollment in the study, with at least one twin or other sibling of the same gender within 5 years of age and without a recognized systemic rheumatic disorder or other autoimmune disease available for study.
Twin-sibling inclusion criteria:
-Children or adults who are twins or other siblings of a proband sharing the same biological parents, but without a recognized systemic rheumatic or autoimmune disorder, of the same gender and within 5 years of age of the proband. If monozygotic twins are enrolled from a family, another unaffected non-twin sibling sharing the same biological parents will be enrolled for each proband if available to allow for log-linear genetic analyses. All probands and unaffected siblings need to be at least one year of age at the time of autoimmune disease diagnosis. In the case of triplets or greater multiples, all such siblings are eligible for enrollment.
Parent inclusion criteria:
-Individuals who are the genetic father and mother of the proband and twin-sib. Both parents will be enrolled whenever possible.
Healthy volunteer inclusion criteria:
Healthy controls, recruited in part via the NIH Healthy Volunteers program, and as reasonably as possible, matched to a subset of probands based on age (within 5 years), gender, and race (when feasible). Healthy volunteers should be in good health, without
a recognized systemic rheumatic disorder or other autoimmune disease, and should not be taking antiinflammatory medicines, including nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.
For all subjects: ability of the subject or parents/legal guardians to provide informed consent to all aspects of the study after full protocol information is provided.
Should a participant enroll at a time when his/her twin/sibling is willing and able to give informed consent, but his/her twin/sibling never enrolls (eg. Due to no longer being willing or able to give informed consent), the enrolled participant will remain in the study and his/her data will be used in the analyses not pertinent to his/her twin/sibling. Data analysis will also occur in this manner should the enrolled participant s sibling enroll, but never send in blood samples and/or questionnaires.
Exclusion criteria for all protocol subjects:
- severe trauma or vaccinations within 8 weeks of enrollment;
- Still s disease/systemic-onset or pauciarticular JRA;
- medical illness that in the judgment of the investigators does not allow safe blood draws or other clinical evaluations needed for study participation;
- cognitive impairment;
- inability to give informed assent or consent.
Exclusion criteria for twin-sibs:
Not sharing the same biological parents (being half-brothers or half-sisters). Known criteria for systemic rheumatic disease or autoimmune disease (for example: RA/JRA, SLE/JSLE, SSc/JSSc, IIM/JIIM, Type 1 diabetes, Psoriasis, Still s disease/systemic-onset or pauciarticular JRA, Celiac sprue, Autoimmune thyroid disease, Idiopathic Thrombocytopenia Purpura, Multiple sclerosis, Myasthenia gravis, Systemic vasculitis or Vitiligo).
Exclusion criteria for healthy volunteers:
Recognized systemic rheumatic disorder or other autoimmune disease, history of cancer or taking anti-inflammatory medicines, including nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, severe trauma or vaccinations within 8 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00055055
|United States, Maryland|
|National Institutes of Health Clinical Center|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Lisa G Rider, M.D.||National Institute of Environmental Health Sciences (NIEHS)|
|Responsible Party:||National Institute of Environmental Health Sciences (NIEHS)|
|Other Study ID Numbers:||
|First Posted:||February 17, 2003 Key Record Dates|
|Last Update Posted:||May 26, 2023|
|Last Verified:||October 28, 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Plan Description:||.It is not yet known if there will be a plan for IPD availability, we are still deciding|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Immune System Diseases
Nervous System Diseases